Zantac Lawsuit Attorneys
If you or a loved one has been diagnosed with cancer after taking Zantac, Provost Umphrey is seeking justice for you.
Zantac, also known as ranitidine, is an over-the-counter (OTC) and prescription H2 blocker used to treat heartburn, GERD, esophagitis, gastritis and other problems of the stomach or esophagus.
The Recall
UPDATE: On April 1, 2020, the FDA requested the removal of all ranitidine products from the market due to the levels of NDMA found in laboratory testing.
In September 2019, the U.S. Food and Drug Administration (FDA) announced that Zantac contains low levels of N-nitrosodimethylamine (NDMA). NDMA is currently classified as a probable human carcinogen meaning it is a substance that could cause cancer. These findings were based on laboratory results. Zantac’s manufacturer called for a voluntary recall of the following products:
- Zantac 150®
- Zantac 150® Cool Mint
- Zantac 75®
After the FDA’s notice, Walgreens, CVS, Kroger, Target, Rite-Aid, and Walmart pulled medication containing NDMA from its shelves.
Types of Cancer
N-nitrosodimethylamine or NDMA can cause cancer of the:
- Bladder
- Brain
- Colon
- Kidney
- Liver
- Esophagus
- Stomach
- Pancreas
Testing
FDA testing is still ongoing. In November of 2019, the FDA released its results of laboratory testing of ranitidine. NDMA levels were present in all samples tested, with some reaching beyond the .32 parts per million daily (ppm) limit.
What You Can Do
If you have been diagnosed with cancer after taking Zantac, you may be entitled to compensation. The trial lawyers at Provost Umphrey Law Firm have decades of experience investigating and successfully trying medical product liability cases.
We provide our clients with a guarantee that you will not owe us anything if we are unable to secure financial compensation for your suffering. All the case information you provide our firm will remain confidential.
If you or a loved one has been diagnosed with cancer after taking Zantac, call today for a free case evaluation at (888) 588-1695.
